Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of Hemay005 tablets in moderate-to-severe atopic dermatitis
CTR20222690Phase 2Active
- Sponsor
- Hemay Pharmaceutical Technology
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mufemilast in atopic dermatitis (AD), sponsored by Hemay Pharmaceutical Technology. Started Oct 2022; status: active.
02
Drugs
mufemilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20222690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222690.